drugset / Trial / NCT03155191
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.
Timeline
- Start
- 2017-06-01
- Primary completion
- 2035-03-31
- Completion
- 2035-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TBI1501 | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | TBI1501 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | TBI1501 | Cell therapy | 3e+06 cells/kg | Intravenous |